Investors
To download our documents
OSE Immunotherapeutics is listed since 30th March 2015 on the regulated market of Euronext Paris
FR0012127173
OSE
Continuous
23,560,111 shares as of May 31, 2026
Eligible to Long-Only Deferred Settlement Service
2025 Full-Year Financial Update and Statements
2026 1Q Cash Position
Annual General Meeting
2026 First-Half Financial Update and Statements
2026 3Q Cash Position
2026 4Q Cash Position